688265.SH
南模生物
SSE · Healthcare · Biotechnology · CN
CNY 40.03
−5.37%Year over year
Reported trailing growth
- Revenue
- +11.9%
- EBITDA
- —
- EBIT
- +141.2%
- EPS
- +86.9%
- Free cash flow
- -54.2%
- Operating cash flow
- +20.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +11.6%
- EBITDA
- +78.9%
- EBIT
- +975.6%
- Net income
- +384.0%
- EPS
- +425.0%
- Free cash flow
- +10.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026